Skip to main content
ETON
NASDAQ Life Sciences

Eton's ET-700 Pilot: Better Tolerability, Weaker Copper Blocking Than GALZIN

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$47.15
Mkt Cap
$1.348B
52W Low
$14.27
52W High
$66.37
52W Position info
230% above low
Off High info
29% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ETON has more than doubled off its 52-week low of $14.27.

Summary

Eton reported preliminary ET-700 pilot results: far fewer treatment-related side effects than GALZIN, but weaker inhibition of copper absorption, with faster-release reformulations now slated for 2027 study arms.


Key Events · Product Development and Regulatory · ETON

  • ET-700 Pilot Results Announced

    Randomized, double-blind, placebo-controlled study in 36 healthy participants; 29 met per-protocol criteria for the primary copper-uptake analysis.

  • Tolerability Clearly Better Than GALZIN

    Treatment-related adverse events occurred in 1 of 12 ET-700 participants versus 8 of 12 on GALZIN (17 total events) and 3 of 12 on placebo; no serious adverse events in any arm.

  • Copper Blocking Weaker Than GALZIN

    Hepatic copper uptake fell 12% with ET-700 versus 46% with GALZIN and an 11% increase with placebo; the intention-to-treat analysis showed 18% versus 58% with GALZIN (p=0.023).

  • Faster-Release Reformulation Pushed to 2027

    Eton is advancing faster-release formulations and intends to test them in additional study arms in 2027, so a refined ET-700 profile is at least a year away.


Analysis · ETON · Life Sciences

ET-700 is one of six late-stage candidates, and this first human data cuts both ways. Tolerability was clearly better — 1 of 12 ET-700 participants had a treatment-related adverse event versus 8 of 12 on GALZIN — but the efficacy endpoint went the wrong way: hepatic copper uptake fell only 12% on ET-700 versus 46% on GALZIN, and the intention-to-treat analysis showed GALZIN's advantage was statistically significant (p=0.023). Management is pivoting to faster-release formulations with new study arms in 2027, which pushes any meaningful ET-700 readout further out. The commercial franchise (Q2 revenue of $37.6 million, up 99%) is unaffected, so this is a pipeline-timeline story rather than a thesis change.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ETON was trading at $47.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $14.27 to $66.37. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ETON - Latest Insights

ETON
Nov 06, 2026, 9:04 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $58.86
Real-time Price: $62.41 info
Change: +$3.55 (+6%) info
Market Cap: $1.8B info
ETON
Nov 05, 2026, 4:32 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $57.90
Real-time Price: $62.41 info
Change: +$4.51 (+8%) info
Market Cap: $1.8B info
ETON
Nov 05, 2026, 4:13 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $56.06
Real-time Price: $62.41 info
Change: +$6.35 (+11%) info
Market Cap: $1.8B info
ETON
Nov 05, 2026, 4:05 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $47.15
Real-time Price: $62.41 info
Change: +$15.26 (+32%) info
Market Cap: $1.8B info
ETON
Nov 05, 2026, 4:01 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $58.85
Real-time Price: $62.41 info
Change: +$3.56 (+6%) info
Market Cap: $1.8B info